Neurobiology of Disease (Oct 2013)
Association between caffeine intake and age at onset in Huntington's disease
- Clémence Simonin,
- Cécile Duru,
- Julia Salleron,
- Pascale Hincker,
- Perrine Charles,
- Arnaud Delval,
- Katia Youssov,
- Sylvie Burnouf,
- Jean-Philippe Azulay,
- Christophe Verny,
- Clarisse Scherer,
- Christine Tranchant,
- Cyril Goizet,
- Sabrina Debruxelles,
- Luc Defebvre,
- Bernard Sablonnière,
- Monique Romon-Rousseaux,
- Luc Buée,
- Alain Destée,
- Olivier Godefroy,
- Alexandra Dürr,
- Bernhard Landwehrmeyer,
- Anne-Catherine Bachoud-Levi,
- Florence Richard,
- David Blum,
- Pierre Krystkowiak
Affiliations
- Clémence Simonin
- Department of Neurology and Movement Disorders, Roger Salengro University Hospital, Lille, France; Inserm UMR837, “Evènements moléculaires associés aux stades précoces de la maladie de Parkinson”, Lille, France; Lille-Nord de France University Hospital, University Lille 2/Law & Health, Jean-Pierre Aubert Research Centre, IFR114, IMPRT, Lille, France; Correspondence to: C. Simonin, Service de Neurologie A, Hôpital Salengro, 59037 Lille cedex, France. Fax: +33 320446680.
- Cécile Duru
- Department of Clinical Neurophysiology, Amiens University Hospital, Amiens, France; Department of Neurology, Amiens University Hospital, Amiens, France; EA 4559, UPJV, Amiens, France
- Julia Salleron
- Department of Biostatistics, Lille Nord de France University Hospital, EA 2694 Lille, France
- Pascale Hincker
- Department of Nutrition, Lille Nord de France University Hospital, Lille, France
- Perrine Charles
- Department of Genetics and Cytogenetics, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; AP-HP, Centre de référence maladie rare/maladie de Huntington, Créteil, Paris, France
- Arnaud Delval
- Department of Neurology and movement disorders, Roger Salengro University Hospital, EA 4559, University Lille 2/Law & Health, Lille Nord de France University Hospital, Lille, France
- Katia Youssov
- AP-HP, Centre de référence maladie rare/maladie de Huntington, Créteil, Paris, France
- Sylvie Burnouf
- Inserm UMR837, “Alzheimer & Tauopathies”, Lille, France; Lille-Nord de France University, CHRU-Lille, USDL, Faculté de Médecine, Jean-Pierre Aubert Research Center, IMPRT, Lille, France
- Jean-Philippe Azulay
- Department of Clinical Neurosciences, Movement disorders unit, la Timone University Hospital, Marseille, France
- Christophe Verny
- Centre de référence maladies rares/neurogénétiques, Department of Neurology, Angers University Hospital, Angers, France; UMR Cnrs 6214, UMR Inserm U771, Angers, France
- Clarisse Scherer
- Centre de référence maladies rares/neurogénétiques, Department of Neurology, Angers University Hospital, Angers, France
- Christine Tranchant
- Department of neurology, Strasbourg University Hospital, Strasbourg, France
- Cyril Goizet
- Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA4576, and Department of Medical Genetics, Pellegrin Hospital, Bordeaux University Hospital, Bordeaux, France
- Sabrina Debruxelles
- Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA4576, and Department of Medical Genetics, Pellegrin Hospital, Bordeaux University Hospital, Bordeaux, France
- Luc Defebvre
- Department of Neurology and Movement Disorders, Roger Salengro University Hospital, Lille, France
- Bernard Sablonnière
- Inserm UMR837, “Alzheimer & Tauopathies”, Lille, France; Lille-Nord de France University, CHRU-Lille, USDL, Faculté de Médecine, Jean-Pierre Aubert Research Center, IMPRT, Lille, France; UF Neurobiologie, Centre de Biologie-pathologie, Lille University Hospital, France
- Monique Romon-Rousseaux
- Department of Nutrition, Lille Nord de France University Hospital, Lille, France
- Luc Buée
- Inserm UMR837, “Alzheimer & Tauopathies”, Lille, France; Lille-Nord de France University, CHRU-Lille, USDL, Faculté de Médecine, Jean-Pierre Aubert Research Center, IMPRT, Lille, France
- Alain Destée
- Department of Neurology and Movement Disorders, Roger Salengro University Hospital, Lille, France; Inserm UMR837, “Evènements moléculaires associés aux stades précoces de la maladie de Parkinson”, Lille, France; Lille-Nord de France University Hospital, University Lille 2/Law & Health, Jean-Pierre Aubert Research Centre, IFR114, IMPRT, Lille, France
- Olivier Godefroy
- Department of Neurology, Amiens University Hospital, Amiens, France; EA 4559, UPJV, Amiens, France
- Alexandra Dürr
- Department of Genetics and Cytogenetics, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; AP-HP, Centre de référence maladie rare/maladie de Huntington, Créteil, Paris, France
- Bernhard Landwehrmeyer
- Department of Neurology, University of Ulm, Ulm, Germany
- Anne-Catherine Bachoud-Levi
- AP-HP, Centre de référence maladie rare/maladie de Huntington, Créteil, Paris, France
- Florence Richard
- Unité d'épidémiologie, Pôle de Santé Publique, Lille Nord de France University Hospital, France; Inserm U744, Lille, France; Institut Pasteur de Lille, Lille, France
- David Blum
- Inserm UMR837, “Alzheimer & Tauopathies”, Lille, France; Lille-Nord de France University, CHRU-Lille, USDL, Faculté de Médecine, Jean-Pierre Aubert Research Center, IMPRT, Lille, France; Correspondence to: D. Blum, Inserm UMR837, Place de Verdun, 59045, Lille Cedex, France. Fax: +33 320538562.
- Pierre Krystkowiak
- Department of Neurology, Amiens University Hospital, Amiens, France; EA 4559, UPJV, Amiens, France; Correspondence to: P. Krystkowiak, Service de Neurologie, CHU d'Amiens, 80054 Amiens Cedex, France. Fax: +33 22668244.
- Journal volume & issue
-
Vol. 58
pp. 179 – 182
Abstract
Habitual consumption of caffeine, a non-selective adenosine receptor (AR) antagonist, has been suggested to be beneficial in Parkinson's and Alzheimer's diseases. Experimental evidence support that ARs play a role in Huntington's disease (HD) raising the hypothesis that caffeine may be a life-style modifier in HD. To determine a possible relationship between caffeine consumption and age at onset (AAO) in HD, we retrospectively assessed caffeine consumption in 80 HD patients using a dietary survey and determined relationship with AAO. Following adjustment for gender, smoking status and CAG repeat length, caffeine consumption greater than 190 mg/day was significantly associated with an earlier AAO. These data support an association between habitual caffeine intake and AAO in HD patients, but further studies are warranted to understand the link between these variables.
